Your search for tofacitinib returned 40 results

The researchers found that significantly more patients receiving tofacitinib 5mg and tofacitinib 10mg versus placebo achieved a ≥50% reduction in the Nail Psoriasis Severity Index (NAPSI) score from baseline (NAPSI50)

Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).

The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.

Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.

Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.

A drug used for rheumatoid arthritis might regrow hair in alopecia areata (AA) patients, according to a study published online September 22 in JCI Insight.

Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met

Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.

No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept

For patients with rheumatoid arthritis (RA), moderate changes in lipids are observed after treatment with tocilizumab or tofacitinib.